https://www.streetinsider.com/Globe+Newswire/Apollomics+Completes+Enrollment+in+Phase+3+Bridging+Study+of+Uproleselan+in+Chinese+Patients+with+RelapsedRefractory+Acute+Myeloid+Leukemia/22585245.html